Drug Profile
BMS 986299
Alternative Names: BMS-986299Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Immunomodulators; NLRP3 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 18 Aug 2023 Chemical structure information added
- 02 Jun 2023 Efficacy and adverse event data from phase I trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 17 May 2022 Bristol-Myers Squibb terminates a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Monotherapy) in USA (unspecified route) due to changed business objectives (NCT03444753)